- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Simon Rule, MD: The Impact of Subcutaneous Rituximab on Clinical Practice
Simon Rule, MD, Plymouth University Medical School, discusses how subcutaneous rituximab has impacted clinical practice.
Transcript:
In my own hospital, we’ve been using subcutaneous rituximab for quite a few years now. We did the early studies, and it’s made a massive difference, not just with respect to your day unit, your nursing resource, the chair time, but also with respect to the patients.
So, we did a time-and-motion study, which was published some time ago, comparing intravenous with subcutaneous. We actually timed patients from the minute they walked in the hospital door to the time they walked out.
Whilst on the face of it, an [intravenous] infusion is 90 minutes, the patient’s actually in the hospital for nearly 4 horus by the time they’re in and out. With a subcutaneous, you literally can give and go. You don’t have to give any prophylaxis. So the patient has the injection, it takes about 5 minutes, and they can leave. So that’s a big, big difference. It’s a fixed syringe, so you don’t have to preorder it.
You can give it outside the hospital setting, of course, and the big difference we saw is maybe not so much for the patient but for the relative; because these patients are often elderly, they’ve got their son or daughter taking off work to go to the hospital. If it only takes half an hour rather than all afternoon, then that’s a big, big impact. I think that’s often not looked at particularly. We just focus on how long the patient’s in the chair getting the drug for, but actually, it’s a big impact.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
